- Home
- CGNT vs ANAB Comparison
CGNT vs ANAB Comparison
Compare CGNT & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- ANAB
- Stock Information
- Founded
- CGNT 2020
- ANAB 2005
- Country
- CGNT Israel
- ANAB United States
- Employees
- CGNT N/A
- ANAB N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- CGNT Technology
- ANAB Health Care
- Exchange
- CGNT Nasdaq
- ANAB Nasdaq
- Market Cap
- CGNT 657.1M
- ANAB 630.2M
- IPO Year
- CGNT N/A
- ANAB 2017
- Fundamental
- Price
- CGNT $8.46
- ANAB $20.16
- Analyst Decision
- CGNT Hold
- ANAB Buy
- Analyst Count
- CGNT 1
- ANAB 10
- Target Price
- CGNT N/A
- ANAB $48.00
- AVG Volume (30 Days)
- CGNT 289.4K
- ANAB 427.6K
- Earning Date
- CGNT 09-09-2025
- ANAB 11-04-2025
- Dividend Yield
- CGNT N/A
- ANAB N/A
- EPS Growth
- CGNT N/A
- ANAB N/A
- EPS
- CGNT N/A
- ANAB N/A
- Revenue
- CGNT $376,566,000.00
- ANAB $123,164,000.00
- Revenue This Year
- CGNT $14.94
- ANAB $11.40
- Revenue Next Year
- CGNT $9.57
- ANAB $8.17
- P/E Ratio
- CGNT N/A
- ANAB N/A
- Revenue Growth
- CGNT 14.04
- ANAB 304.17
- 52 Week Low
- CGNT $6.38
- ANAB $12.21
- 52 Week High
- CGNT $11.66
- ANAB $40.55
- Technical
- Relative Strength Index (RSI)
- CGNT 44.61
- ANAB 41.04
- Support Level
- CGNT $8.15
- ANAB $20.61
- Resistance Level
- CGNT $8.81
- ANAB $23.64
- Average True Range (ATR)
- CGNT 0.32
- ANAB 1.22
- MACD
- CGNT -0.02
- ANAB 0.23
- Stochastic Oscillator
- CGNT 21.83
- ANAB 10.92
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).